Grünberg K, Timmers M C, de Klerk E P, Dick E C, Sterk P J
Department of Pulmonology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Am J Respir Crit Care Med. 1999 Oct;160(4):1375-80. doi: 10.1164/ajrccm.160.4.9810083.
Exacerbations of asthma are often associated with rhinovirus infections. However, it has not been investigated whether rhinovirus infection can induce variable airway obstruction in asthma. We examined the effect of experimental rhinovirus 16 (RV16) infection on daily home recordings of FEV(1) in 27 subjects (nonsmoking, atopic, mildly asthmatic) who participated in a parallel placebo-controlled study. The subjects used a microspirometer to record FEV(1) three times daily from 4 d before until 10 d after RV16 (n = 19) or placebo (n = 8) inoculation. In addition, symptoms of asthma and symptoms of common cold were scored. Airway hyperresponsiveness to histamine was measured 3 d before and on Days 4 and 11 after RV16/placebo administration. Home recordings of FEV(1) decreased significantly after RV16 infection, reaching a minimum 2 d after inoculation (ANOVA, p </= 0.005), which was significantly different from placebo (p </= 0.004). In the RV16 group the lowest FEV(1) (expressed as a percentage of personal best) during Days 0-3 after infection (mean +/- SEM: 78.7 +/- 2.6% versus baseline: 85.6 +/- 1.2%, p = 0.008) correlated significantly with the cold score (r = -0.47, p = 0.04), asthma score (r = -0.47, p = 0.04), and with the decrease in airway hyperresponsiveness on Day 4 as compared with baseline (r = 0.50, p = 0.03). We conclude that experimental RV16 infection augments variable airway obstruction in subjects with asthma. This favors a causative role for rhinovirus colds in asthma exacerbations, and is in keeping with rhinovirus-induced worsening of airway inflammation.
哮喘发作常与鼻病毒感染有关。然而,鼻病毒感染是否会在哮喘中诱发可变气道阻塞尚未得到研究。我们在27名受试者(非吸烟、特应性、轻度哮喘)中检测了实验性鼻病毒16型(RV16)感染对每日家庭FEV(1)记录的影响,这些受试者参与了一项平行的安慰剂对照研究。受试者使用微型肺活量计,从RV16(n = 19)或安慰剂(n = 8)接种前4天至接种后10天,每天记录3次FEV(1)。此外,对哮喘症状和普通感冒症状进行评分。在RV16/安慰剂给药前3天以及给药后第4天和第11天测量气道对组胺的高反应性。RV16感染后,家庭FEV(1)记录显著下降,在接种后2天降至最低(方差分析,p≤0.005),这与安慰剂组有显著差异(p≤0.004)。在RV16组中,感染后第0 - 3天最低FEV(1)(以个人最佳值的百分比表示)(均值±标准误:78.7±2.6%,而基线为:85.6±1.2%,p = 0.008)与感冒评分(r = -0.47,p = 0.04)、哮喘评分(r = -0.47,p = 0.04)以及与第4天相比基线时气道高反应性的降低(r = 0.50,p = 0.03)显著相关。我们得出结论,实验性RV16感染会加重哮喘患者的可变气道阻塞。这支持鼻病毒感冒在哮喘发作中起致病作用,并与鼻病毒引起的气道炎症恶化一致。